PP_1170x120_10-25-21

Roger Connor

GSK to produce 1 billion doses of pandemic vaccine adjuvant in 2021 to support multiple COVID-19 vaccine collaborations

GSK to produce 1 billion doses of pandemic vaccine adjuvant in 2021 to support multiple COVID-19 vaccine collaborations

LONDON — GSK has confirmed its intention to manufacture 1 billion doses of its pandemic vaccine adjuvant system, in 2021, to support the development of multiple adjuvanted COVID-19 vaccine candidates. GSK believes that its pandemic adjuvant technology could make a significant contribution against COVID-19.  As demonstrated in the last flu pandemic, GSK’s pandemic adjuvant can